Home
Resources
Publications
n-Dodecyl-β-D-maltoside Inhibits Aggregation of Human interferon-β-1b and Reduces Its Immunogenicity

n-Dodecyl-β-D-maltoside Inhibits Aggregation of Human interferon-β-1b and Reduces Its Immunogenicity

Robert A Rifkin, Edward T Maggio, Sonny Dike, Douglas A Kerr, Michael Levy

J Neuroimmune Pharmacol. 2011 Mar;6(1):158-62.

PMID: 20532646

Abstract:

The development of neutralizing antibodies to the protein drug interferon-β is a significant impediment to its use in the treatment of multiple sclerosis. Neutralizing antibodies to interferon-β arise from aggregation of the peptide during manufacturing and storage. We tested the ability of dodecylmaltoside, a nontoxic alkylsaccharide surfactant, to reduce aggregation of interferon-β in vitro and to reduce its immunogenicity in vivo. Interferon-β, in solution with and without dodecylmaltoside, was periodically evaluated for aggregation by light scatter for 1 month. Interferon-β, with and without dodecylmaltoside, was given 3 days/week for 1 month to mice; the sera of these mice were analyzed for anti-interferon-β antibodies by ELISA. Dodecylmaltoside reduces the aggregation of interferon-β in vitro and its immunogenicity in vivo. Our positive findings warrant additional tests of dodecylmaltoside as a therapeutic adjuvant in rodent models of multiple sclerosis.

Chemicals Related in the Paper:

Catalog Number	Product Name	Structure	CAS Number	Price
AP69227936	n-Dodecyl β-D-maltoside		69227-93-6	Price

As a specialist in analytical chemical Products, Alfa Chemistry offers consumers a wealth of raw materials and a full range of technologies and services.

QUICK LINKS

HEADQUARTERS

Tel:

Fax:

Email: